Alex Delbridge PhD

Biotech Venture Capital | Brandon Capital

Melbourne, Victoria, Australia

About

Experience

  • Principal | Investment Team at Brandon Capital
    Aug 2025 - Present · 1 yr

  • Board Observer at BridgeBio Oncology Therapeutics
    May 2024 - Jul 2025 · 1 yr 3 mos

    Trading on the NASDAQ (Ticket: BBOT) following de-SPAC transaction closed in August 2025. https://investors.bbotx.com/news-releases/news-release-details/bbot-debuts-publicly-traded-company-focused-ras-pathway

  • Board Observer at NRG Therapeutics
    Jun 2022 - Jul 2025 · 3 yrs 2 mos

  • Senior Investment Associate at Omega Funds
    Aug 2021 - Jul 2025 · 4 yrs

  • Board Observer at Scorpion Therapeutics
    May 2022 - Jun 2025 · 3 yrs 2 mos

    Acquired by Eli Lilly in January 2025 for up to $2.5B. https://investor.lilly.com/news-releases/news-release-details/lilly-acquire-scorpion-therapeutics-mutant-selective-pi3ka